Evidence map›Paper›PMID 35236844›Full record

ArticleNPJ vaccines2022

Acute kidney rejection after anti-SARS-CoV-2 virus-vectored vaccine-case report.

Matej Vnučák, Karol Graňák, Monika Beliančinová, Miloš Jeseňák, Katarína Kajová Macháleková, Jakub Benko, Matej Samoš, Ivana Dedinská

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matej VnučákTransplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia.ORCID http://orcid.org/0000-0003-1761-1425
Karol GraňákTransplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia. granak.k@gmail.com.ORCID http://orcid.org/0000-0001-8834-0365
Monika BeliančinováTransplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia.
Miloš JeseňákDepartment of Children and Adolescents, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia.
Katarína Kajová MachálekováDepartment of Pathology, St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia.
Jakub Benko1st Department of Internal Diseases, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia.
Matej Samoš1st Department of Internal Diseases, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia.
Ivana DedinskáTransplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 infection remains a threat to the health systems of many countries. Potential success in the fight against the COVID-19 pandemic is the vaccination of high-risk groups, including patients with end-stage kidney disease (ESKD) and after solid organ transplantation (SOT). Immunosuppression in kidney transplant recipients can also reduce the immunogenicity of SARS-CoV-2 vaccines (varied by vaccine platform), available data suggest that they are efficacious in approximately 50-70%, compared to non-transplant situations. In this paper, we present a newly developed acute humoral and cellular rejection with acute allograft failure and need of hemodialysis 14 days after administration of the adenovirus vectored SARS-CoV-2 vaccine (AstraZeneca; CHADOx1, AZD1222). This occurred in a patient who previously had an asymptomatic COVID-19 infection. Case reports of acute allograft rejection after vaccination against SARS-CoV-2 can help stratify risk groups of patients who develop hyperimmune reactions. However, it is also possible that those with a previous mild primary COVID-19 infection may also develop acute allograft rejections upon COVID-19 re-infection.

Identifiers

PMID35236844
PMCPMC8891308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.